1234015-57-6

1234015-57-6 structure
1234015-57-6 structure
  • Name: Prexasertib Mesylate Hydrate
  • Chemical Name: Prexasertib Mesylate Hydrate
  • CAS Number: 1234015-57-6
  • Molecular Formula: C19H25N7O6S
  • Molecular Weight: 479.51
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2019-02-08 20:58:42
  • Modify Date: 2024-01-12 10:55:27
  • Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a potent, selective, ATP competitive CHK1 and CHK2 inhibitor, with a Ki of 0.9 nM for CHK1 and IC50s of <1 nM, 8 nM for CHK1 and CHK2, respectively. Prexasertib Mesylate Hydrate inhibits HT-29 CHK1 autophosphorylation (S296) and HT-29 CHK2 autophosphorylation (S516). Prexasertib Mesylate Hydrate shows potent anti-tumor activity, significantly abrogates the G2/M checkpoint in p53 deficient HeLa cells with an EC50 of 9 nM[1].

Name Prexasertib Mesylate Hydrate
Synonyms Prexasertib (Mesylate Hydrate)
Description Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a potent, selective, ATP competitive CHK1 and CHK2 inhibitor, with a Ki of 0.9 nM for CHK1 and IC50s of <1 nM, 8 nM for CHK1 and CHK2, respectively. Prexasertib Mesylate Hydrate inhibits HT-29 CHK1 autophosphorylation (S296) and HT-29 CHK2 autophosphorylation (S516). Prexasertib Mesylate Hydrate shows potent anti-tumor activity, significantly abrogates the G2/M checkpoint in p53 deficient HeLa cells with an EC50 of 9 nM[1].
Related Catalog
Target

Chk1:0.9 nM (Ki)

Chk1:<1 nM (IC50)

Chk2:8 nM (IC50)

In Vitro Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is an ATP competitive CHK1 inhibitor, with a Ki of 0.9 nM and an IC50 of <1 nM[1]. Prexasertib (LY2606368) shows high anti-tumor activity against U-2 OS, Calu-6 and HeLa cells (IC50, 3, 3, 37 nM, respectively), causes DNA damage during S-phase requiring CDC25A and CDK2 at 4 μM[1]. Prexasertib (0-20 nM) synergizes with olaparib (0-20 μM) to decrease cell viability in HGSOC cells[2].
Animal Admin Prexasertib (1, 3.3 or 10 mg/kg s.c.) is well tolerated, and significantly inhibits tumor inhibition in mice bearing Calu-6 xenograft tumors[1].
References

[1]. King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-13.

[2]. Brill E, et al. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget. 2017 Oct 31;8(67):111026-111040.

Molecular Formula C19H25N7O6S
Molecular Weight 479.51
Storage condition 2-8℃